Ibuprofeno frente a indometacina en el tratamiento del conducto arterioso persistente del prematuro

Navarro, A.E.; Sánchez, Amaury Flores; Gilino, C. Fernández; Moreno, J. C.; Macián, Isabel Izquierdo; Laso, A. Gutiérrez; Sopena, F. Morcillo

doi:10.1157/13078483

Cited by 24 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-nine studies were excluded after full-text screening (eTable 3 in Supplement 3). The clinical and methodological characteristics of the included studies appear in eTable 4 in Supplement 3 . The studies were published between 1980 and 2017.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants

Mitra

Flórez

Tamayo

et al. 2018

JAMA

255

222

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…Sixty-one of the 68 studies were published in English. The remaining were published in Polish, Turkish, Persian, Spanish, Korean, Chinese, and French …”

Section: Resultsmentioning

confidence: 99%

Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants

Mitra

Flórez

Tamayo

et al. 2018

JAMA

255

222

View full text Add to dashboard Cite

show abstract

“…recorded in three of them [8][9][10]. Working with pooled data, it may be seen that 191 infants received ibuprofen, ductal closure occurring in 140 of them (73.3%).…”

Section: Responders Not Withdrawn Remaining Patients Totalmentioning

confidence: 99%

Correction: Net Efficacy Adjusted for Risk (NEAR): A Simple Procedure for Measuring Risk:Benefit Balance

Boada¹,

Boada²,

García-Sáiz³

et al. 2010

PLoS ONE

View full text Add to dashboard Cite

Background: Although several mathematical models have been proposed to assess the risk:benefit of drugs in one measure, their use in practice has been rather limited. Our objective was to design a simple, easily applicable model. In this respect, measuring the proportion of patients who respond favorably to treatment without being affected by adverse drug reactions (ADR) could be a suitable endpoint. However, remarkably few published clinical trials report the data required to calculate this proportion. As an approach to the problem, we calculated the expected proportion of this type of patients.Methodology/Principal Findings: Theoretically, responders without ADR may be obtained by multiplying the total number of responders by the total number of subjects that did not suffer ADR, and dividing the product by the total number of subjects studied. When two drugs are studied, the same calculation may be repeated for the second drug. Then, by constructing a 262 table with the expected frequencies of responders with and without ADR, and non-responders with and without ADR, the odds ratio and relative risk with their confidence intervals may be easily calculated and graphically represented on a logarithmic scale. Such measures represent ''net efficacy adjusted for risk'' (NEAR). We assayed the model with results extracted from several published clinical trials or meta-analyses. On comparing our results with those originally reported by the authors, marked differences were found in some cases, with ADR arising as a relevant factor to balance the clinical benefit obtained. The particular features of the adverse reaction that must be weighed against benefit is discussed in the paper. Conclusion:NEAR representing overall risk-benefit may contribute to improving knowledge of drug clinical usefulness. As most published clinical trials tend to overestimate benefits and underestimate toxicity, our measure represents an effort to change this trend.

show abstract

Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants

Ohlsson

Walia

Shah

2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Ibuprofeno frente a indometacina en el tratamiento del conducto arterioso persistente del prematuro

Cited by 24 publications

References 34 publications

Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants

Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants

Correction: Net Efficacy Adjusted for Risk (NEAR): A Simple Procedure for Measuring Risk:Benefit Balance

Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants

Contact Info

Product

Resources

About